ClinicalTrials.gg
TerminatedNCT06505018ALTERNATIVEUpdated Sep 29, 2026

Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

An interventional study of Cureety techcare in Metastatic Triple-Negative Breast Carcinoma, sponsored by UNICANCER. Terminated at 51 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by UNICANCER · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
The study was terminated prematurely due to insufficient patient recruitment.
Updated Sep 29, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Triple Negative Breast Neoplasms with a site in France — 35 open to participants now, 66 under way, 13 of them phase 3. Triple Negative Breast Neoplasms · France.

Enrollment
107th of 119
31 · median 182
Started
2024
with 15 others
No phase
14 of 125
8 open now
Registered
104th of 125
by date
Lead sponsor
8 of 125
UNICANCER

Among the 125 studies in Triple Negative Breast Neoplasms with a site in France, this one is the 107th largest by enrollment of the 119 interventional ones that give a count, is one of 16 that started in 2024, is one of 14 with no phase, and was the 104th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

35 of the 125 studies in Triple Negative Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Triple Negative Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.

The main questions it aims to answer are:

  • Is patient quality of life improved by using the telemonitoring platform?
  • Are patients hospitalized less frequently when using the telemonitoring platform?
  • Is the patient overall survival improved by telemonitoring ?

Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.

Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.

03

Conditions studied

  • Metastatic Triple-Negative Breast Carcinoma

Keywords

  • Telemonitoring
  • Triple Negative Breast Cancer
  • Cureety
  • Adverse events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed a written form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
  • Patients ≥18 years of age.
  • Patient with documented triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) \<10%, Her2 negative status).
  • > 6 months as per investigator estimate.
  • Patient initiating a marketed authorized systemic treatment in the metastatic setting.
  • (ECOG) performance status (PS) ≤2.
  • Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
  • Affiliated to the social security system or equivalent health insurance.
  • Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
  • Patient has access to a computer, tablet, or smartphone connected to the Internet.

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial using telemonitoring.
  • Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
  • Patient deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Telemonitoring group

    Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare".

    Device: Cureety techcare

  • No intervention
    Standard-of-care group

Interventions

  • DeviceCureety techcare

    Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient). The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device.

06

What researchers measure

Primary outcomes

  1. Time to definitive Health-Related Quality of life score Deterioration

    The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred. The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life.

    Time frame: At baseline then every 3 months, up to 24 months

  2. Hospitalization-free survival

    Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive.

    Time frame: From randomization to death from any cause, up to 24 months

  3. Overall survival

    overall survival is the length of time from randomization during which patients enrolled in the study remain alive.

    Time frame: From randomization to death from any cause, up to 24 months after last inclusion

Secondary outcomes

  1. Time-to-treatment failure

    Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation.

    Time frame: From randomization to treatment discontinuation, up to 24 months

  2. Toxicity-free survival

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first.

    Time frame: From randomization until the first event, up to 24 months

  3. Time to clinical deterioration

    -Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead).

    Time frame: From randomization, to the date of the first clinical deterioration, up to 24 months

  4. Number of treatment lines

    Number of successive treatment lines offered to the patient from randomization to the end of the study.

    Time frame: Throughout study completion, up to 24 months

  5. Incidence of Adverse Events

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout study completion, up to 24 months

  6. Quality of life questionnaire - Core 30 (QLQ-C30)

    Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At baseline then every 3 weeks, up to 24 months

  7. Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)

    This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items.

    Time frame: At baseline then every 3 weeks, up to 24 months

  8. Treatment compliance and extent of exposure

    The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions.

    Time frame: Throughout study completion, up to 24 months

  9. Compliance with the use of Cureety digital telemonitoring

    Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires.

    Time frame: Throughout study completion, up to 24 months

  10. Satisfaction with Cureety telemonitoring

    Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team \[including nurse, clinical research associate, and investigators\]) satisfied by the regular usage of the Cureety telemonitoring tool.

    Time frame: 3 months after randomisation for the patients and 1 year after the site activation for medical team

  11. Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35

    The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent).

    Time frame: 6 months after randomisation

  12. Socio-economic impact of digital telemonitoring

    Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations

    Time frame: Throughout study completion, up to 24 months after randomization

07

Study locations

51 sites
  • Institut de Cancérologie des Hauts-de-France (ICHF)
    Arras, France
  • Centre Hospitalier d'Auxerre
    Auxerre, France
  • Sainte Catherine - Institut du Cancer Avignon Provence
    Avignon, France
  • CH Aunay-Bayeux
    Bayeux, France
  • Centre Hospitalier Simone Veil de Beauvais
    Beauvais, France
  • ICHF - Centre Pierre Curie
    Beuvry, France
  • Hôpital Simone Veil de Blois
    Blois, France
  • Polyclinique bordeaux nord
    Bordeaux, France
  • Centre Hospitalier Fleyriat
    Bourg-en-Bresse, France
  • Centre de Cancérologie Privé de Caen Maurice Tubiana
    Caen, France
  • Centre Francois Baclesse
    Caen, France
  • Centre hospitalier de Carcasonne
    Carcassonne, France
  • Recherche Oncologie Clinqiue 37 (ROC 37)
    Chambray-lès-Tours, France
  • CH de Cholet
    Cholet, France
  • CH Colmar
    Colmar, France
  • Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
    Creil, France
  • Centre Georges François Leclerc
    Dijon, France
  • Institut Andrée Dutreix
    Dunkirk, France
  • CH Annecy Genevois
    Épagny, France
  • Centre Hospitalier Intercommunal de Fréjus Saint Raphael
    Fréjus, France
  • Groupe Hospitalier Mutualiste de Grenoble
    Grenoble, France
  • CHU de la réunion
    La Réunion, France
  • Clinique Sainte Clotilde
    La Réunion, France
  • Groupe Hospitalier de La Rochelle-Ré-Aunis
    La Rochelle, France
  • CHU Grenoble Alpes
    La Tronche, France
  • Centre Hospitalier Louis Pasteur
    Le Coudray, France
  • Centre Hospitalier Le Mans
    Le Mans, France
  • Centre Hospitalier Emile Roux
    Le Puy-en-Velay, France
  • GHBS Lorient
    Lorient, France
  • Centre Leon Berard
    Lyon, France
  • Clinique de la Sauvegarde
    Lyon, France
  • Hôpital Privé Jean Mermoz
    Lyon, France
  • Institut Paoli Calmettes
    Marseille, France
  • CHI de Mont-de-Marsan et du Pays des Sources
    Mont-de-Marsan, France
  • Centre de Cancérologie du Grand Montpellier
    Montpellier, France
  • Hôpital Privé du Confluent
    Nantes, France
  • Clinique Ambroise-Pare Hartmann
    Neuilly-sur-Seine, France
  • Hôpital Américain de PARIS
    Neuilly-sur-Seine, France
  • CHU de Nimes
    Nîmes, France
  • CHR Orleans
    Orléans, France
  • CHP Sainte-Marie
    Osny, France
  • Diaconesses Croix Saint-Simon Hospital Complex
    Paris, France
  • Centre hospitalier de Pau
    Pau, France
  • CARIO - Hopital Privé des Cotes d'Armor
    Plérin, France
  • CHU de Poitiers
    Poitiers, France
  • Institut Godinot
    Reims, France
  • Clinique Mathilde - Les Hôpitaux Privés Rouennais
    Rouen, France
  • CHU de Saint-Etienne
    Saint-Etienne, France
  • Hia Begin
    Saint-Mandé, France
  • CHU de Tours
    Tours, France
  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, France
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Dec 2025, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Sep 2026 → Dec 2025 and completion Sep 2028 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 17, 2024
StartActual
Jul 25, 2024
Primary completionActual
Dec 1, 2025was Sep 2026
CompletionActual
Dec 12, 2025was Sep 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study was terminated prematurely due to insufficient patient recruitment.
changed Sep 29, 2026
Primary completion
Sep 1, 2026→Dec 1, 2025 (actual)
Sep 29, 2026
Study completion
Sep 2, 2028→Dec 12, 2025 (actual)
Sep 29, 2026
Enrollment
472 (estimated)→31 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Terminated
    Why stopped The study was terminated prematurely due to insufficient patient recruitment.
    Primary completion Sep 1, 2026→Dec 1, 2025 (now actual)
    Study completion Sep 2, 2028→Dec 12, 2025 (now actual)
    Enrollment 472 (estimated)→31 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06505018
Lead sponsor
UNICANCER
Collaborators
Cureety
Responsible party
Sponsor
First posted
Jul 17, 2024
Start date
Jul 25, 2024
Primary completion
Dec 1, 2025
Completion
Dec 12, 2025
Last update
Sep 29, 2026

Study contacts

Jérôme MARTIN-BABAU, MD
principal investigator · Armorican Centre for Radiotherapy, Medical Imaging and Oncology, CARIO, Plérin
Florence JOLY, MD
principal investigator · François Baclesse Center, Caen
Frédéric FITENI, MD
principal investigator · University hospital of Nîmes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion